Haleos Labs Postal Ballot: ₹20 Cr Guarantee Approval

Haleos Labs seeks shareholder approval via postal ballot for a ₹20 Crore corporate guarantee to RBL Bank for subsidiary Mahi Drugs' ECB facility.
The transaction qualifies as a Material RPT under SEBI LODR Reg. 23, representing 5.80% of the company's consolidated turnover of ₹344.72 Crores.
Remote e-voting window runs from March 31, 2026 to April 29, 2026; results to be declared on May 1, 2026.
Mahi Drugs (60%-held subsidiary) reported FY2024-25 standalone turnover of ₹42.27 Crores, PAT loss of ₹3.44 Crores, and holds IVR BB+ Stable credit rating.